SAN DIEGO--(BUSINESS WIRE)--Orexigen™ Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that Carol Baum assumed the position of Vice President of Commercialization effective today. Ms. Baum brings to Orexigen over twelve years of experience in pharmaceutical product marketing and strategic planning. She replaces Jim Lancaster who has served as the Company’s Vice President of Commercialization since August 2006. Mr. Lancaster resigned from Orexigen effective today to spend more time with his family; however, he plans to continue to serve as a consultant to the Company.
